Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure

Documenti analoghi

• Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus
  di: Juliane Rascher, et al.
  Pubblicazione: (2025)
• Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
  di: Xiaoni Wang, et al.
  Pubblicazione: (2025)
• Population pharmacokinetic analysis of the interaction of digoxin with N‐desethylamiodarone in patients with atrial fibrillation and heart failure
  di: Toshinori Hirai, et al.
  Pubblicazione: (2025)
• Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
  di: Maira Visscher, et al.
  Pubblicazione: (2024)
• Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
  di: Clifford G. Banda, et al.
  Pubblicazione: (2024)